New Covid-19 tests to be distributed in UK by Luas Diagnostics following exclusive agreement

New Covid-19 tests to be distributed in UK by Luas Diagnostics following exclusive agreement

 

Two new rapid antibody and antigen tests for Covid-19 from the US will be distributed in the UK and Ireland by Luas Diagnostics, following an exclusive agreement with New York-based Chembio Diagnostic Systems.

 

The antibody test uses a fingerstick to produce a result in 15 minutes and identifies if a patient has been infected and whether it is a current or past infection. The test is available now and is CE marked, meaning it is approved for professional use in the UK and EU.

 

Antibody testing is particularly important now that the introduction of vaccines is imminent, as it will be vital for people to know if the vaccine has stimulated antibody production.

 

The product is easy to use, requiring minimal training for health professionals, and, as it only takes 15 minutes to produce a result, it enables Covid-19 antibody testing to be performed efficiently in a wide variety of occupational health settings. The test differentiates between IgM which is indicative of very early infection and IgG which appears later post infection and remains in the blood for longer.

 

The antigen test is a simple swab test requiring only a nasal sample and gives results in 20 minutes. Performance data shows excellent results versus PCR.

 

The two complementary rapid tests will allow health professionals to determine a complete picture of the status of those they test relative to Covid-19.

 

Examples of where both products may be used include offices, sports facilities, the military, care homes, airports, pharmacies, meeting and conference venues and many other non-clinical sites, as well as clinical sites such as GP surgeries and hospital emergency rooms.

 

Luas Diagnostics has just launched a crowdfunding round through Crowdcube and has already received considerable interest.

 

Brendan Farrell, CEO of Luas Diagnostics, commented: “We are excited to form a partnership with Chembio and look forward to marketing and selling their range of rapid tests into the UK and Irish markets. We see enormous potential for their rapid Covid-19 antigen and antibody products where testing can be performed rapidly, accurately and with minimal training”.

 

www.luasdiagnostics.com /

 

ends

 

 

Notes to editors

 

About Luas Diagnostics

 

Luas Diagnostics is based in Guildford, Surrey and is a UK registered private company, which was founded in 2020.

 

Using enzymes, Luas Diagnostics has developed a new class of sensors that generate electric current upon encountering their molecular target, allowing the development of biomarker assays that are an order of magnitude faster, more versatile, and cheaper to build than current systems in the market.

Because Luas Diagnostics’ diagnostic tests do not require preparation, washing steps, or complex reading mechanisms, the tests can be miniaturised and coupled to a smartphone via Bluetooth for easy readout and uploading of data to repositories in the cloud.

About Chembio Diagnostic Systems

Chembio Diagnostics Systems of Hauppauge New York is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 15-20 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners.

 

The DPP Covid-19 IgM/IgG test, which is CE marked, uses fingerstick whole blood to produce a result in 15 minutes and separately and simultaneously detects both the IgM and IgG antibodies to Sars-CoV-2, thus providing a result showing whether the patient has been infected and whether it is a current or past infection.

 

Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Other products in the Chembio portfolio include Point-of-Care tests for HIV (oral fluid and blood), Syphilis, Zika virus and Ebola.

 

For further information, please contact ChrisLewis@clareville.co.uk; tel 07973 370640.

 

Share this story

Share on email
Email
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn